Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Oncol Rep
    March 2024
  1. WANG Y, Lin W, Zhuang X, Wang X, et al
    Advances in artificial intelligence for the diagnosis and treatment of ovarian cancer (Review).
    Oncol Rep. 2024;51:46.
    >> Share

  2. HOU Y, Zhao X, Nie X
    Enhancing the therapeutic efficacy of NK cells in the treatment of ovarian cancer (Review).
    Oncol Rep. 2024;51:50.
    >> Share

    July 2023
  3. WANG W, Liu S, Lu F, Yang B, et al
    STAT4, a potential predictor of prognosis, promotes CD8 T‑cell infiltration in ovarian serous carcinoma by inducing CCL5 secretion.
    Oncol Rep. 2023;50:140.
    >> Share

    June 2023
  4. YANG X, Li C, Liao X, Liu S, et al
    Paclitaxel induces pyroptosis by inhibiting the volume‑sensitive chloride channel leucine‑rich repeat‑containing 8a in ovarian cancer cells.
    Oncol Rep. 2023;49:115.
    >> Share

  5. TAKAHASHI R, Kamizaki K, Yamanaka K, Terai Y, et al
    Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin.
    Oncol Rep. 2023;49:124.
    >> Share

    May 2023
  6. PEI Y, Li K, Lou X, Wu Y, et al
    [Corrigendum] miR‑1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer.
    Oncol Rep. 2023;49:96.
    >> Share

  7. HAN GH, Yun H, Chung JY, Kim JH, et al
    High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
    Oncol Rep. 2023;49:102.
    >> Share

  8. ZHANG C, Wang R, Li M, Yang Q, et al
    Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.
    Oncol Rep. 2023;49:108.
    >> Share

    March 2023
  9. EOH KJ, Lee DW, Nam EJ, Kim JI, et al
    HOXA‑AS3 induces tumor progression through the epithelial‑mesenchymal transition pathway in epithelial ovarian cancer.
    Oncol Rep. 2023;49:64.
    >> Share

    November 2022
  10. WANG T, Liu J, Huang X, Zhang C, et al
    Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress in ovarian cancer.
    Oncol Rep. 2022;48.
    >> Share

  11. LI J, Li D, Zhang W
    [Retracted] Tumor suppressor role of miR-217 in human epithelial ovarian cancer by targeting IGF1R.
    Oncol Rep. 2022;48.
    >> Share

    June 2022
  12. HE M, Sun HG, Hao JY, Li YL, et al
    [Corrigendum) RNA interferencemediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycininduced apoptosis dependent on JNK activation.
    Oncol Rep. 2022;47.
    >> Share

    May 2022
  13. ZHANG Q, Ding J, Wang Y, He L, et al
    Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review).
    Oncol Rep. 2022;47.
    >> Share

    April 2022
  14. ZHOU X, Zhao F, Wang ZN, Song YX, et al
    [Corrigendum] Altered expression of miR152 and miR148a in ovarian cancer is related to cell proliferation.
    Oncol Rep. 2022;47.
    >> Share

  15. YANG L, Xie HJ, Li YY, Wang X, et al
    Molecular mechanisms of platinumbased chemotherapy resistance in ovarian cancer (Review).
    Oncol Rep. 2022;47.
    >> Share

    March 2022
  16. PARK SA, Kim LK, Park HM, Kim HJ, et al
    Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
    Oncol Rep. 2022;47.
    >> Share

    October 2021
  17. CHENG L, Zhang D, Yan W
    Ultrasoundtargeted microbubble destructionmediated overexpression of Sirtuin 3 inhibits the progression of ovarian cancer.
    Oncol Rep. 2021;46.
    >> Share

  18. LI H, Liu Y, Wang Y, Zhao X, et al
    Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).
    Oncol Rep. 2021;46.
    >> Share

  19. CUI S, Li F
    RHPN1AS1 promotes ovarian carcinogenesis by sponging miR68845p thus releasing TOP2A mRNA.
    Oncol Rep. 2021;46.
    >> Share

    September 2021
  20. PAN Y, Zhang L, Zhang X, Liu R, et al
    [Retracted] Synergistic effects of eukaryotic coexpression plasmidbased STAT3specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.
    Oncol Rep. 2021;46.
    >> Share

    August 2021
  21. WEN J, Han S, Cui M, Wang Y, et al
    [Retracted] Long noncoding RNA MCM3APAS1 drives ovarian cancer progression via the microRNA1433p/TAK1 axis.
    Oncol Rep. 2021;46.
    >> Share

    June 2021
  22. CUI S, Li C
    RHPN1AS1 promotes ovarian carcinogenesis by sponging miR4855p and releasing TPX2 mRNA.
    Oncol Rep. 2021;45.
    >> Share

    May 2021
  23. ZHONG Y, Le F, Cheng J, Luo C, et al
    Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatinresistant SKOV3/DDP ovarian cancer cells.
    Oncol Rep. 2021;45.
    >> Share

  24. LIANG X, Ju J
    Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK.
    Oncol Rep. 2021;45.
    >> Share

  25. LI M, Zhang S, Ma Y, Yang Y, et al
    Role of hsamiR105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
    Oncol Rep. 2021;45.
    >> Share

  26. FREUND E, Miebach L, Stope MB, Bekeschus S, et al
    Hypochlorous acid selectively promotes toxicity and the expression of danger signals in human abdominal cancer cells.
    Oncol Rep. 2021;45.
    >> Share

    April 2021
  27. CAO S, Chen C, Xue J, Huang Y, et al
    [Corrigendum] Silencing of type Igamma phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.
    Oncol Rep. 2021;45:1.
    >> Share

  28. LEE SY, Kwon J, Lee KA
    Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1.
    Oncol Rep. 2021;45.
    >> Share

  29. CHEN J, Chen H, Pan L
    SIRT1 and gynecological malignancies (Review).
    Oncol Rep. 2021;45.
    >> Share

    March 2021
  30. OTA Y, Koizume S, Nakamura Y, Yoshihara M, et al
    Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
    Oncol Rep. 2021;45:1023-1032.
    >> Share

    December 2020
  31. WEI L, He Y, Bi S, Li X, et al
    miRNA199b3p suppresses growth and progression of ovarian cancer via the CHK1/Ecadherin/EMT signaling pathway by targeting ZEB1.
    Oncol Rep. 2020 Dec 11. doi: 10.3892/or.2020.7895.
    >> Share

  32. AN Q, Liu T, Wang MY, Yang YJ, et al
    KRT7 promotes epithelialmesenchymal transition in ovarian cancer via the TGFbeta/Smad2/3 signaling pathway.
    Oncol Rep. 2020 Dec 8. doi: 10.3892/or.2020.7886.
    >> Share

  33. ZHAO L, Liu Z, Deng X, Wang J, et al
    Polyphyllin VII induces mitochondrial apoptosis by regulating the PP2A/AKT/DRP1 signaling axis in human ovarian cancer.
    Oncol Rep. 2020 Dec 2. doi: 10.3892/or.2020.7879.
    >> Share

  34. BRUM MCM, Dos Santos Guimaraes I, Ferreira LB, Rangel LBA, et al
    Osteopontinc isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
    Oncol Rep. 2020 Dec 1. doi: 10.3892/or.2020.7877.
    >> Share

    November 2020
  35. LEE DW, Lee W, Kwon M, Lee HN, et al
    Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
    Oncol Rep. 2020 Nov 11. doi: 10.3892/or.2020.7845.
    >> Share

  36. ZHAO M, Ji H, Fu Q, Cheng Q, et al
    MicroRNA-134-3p inhibits ovarian cancer progression by targeting flap structure-specific endonuclease 1 in vitro.
    Oncol Rep. 2020 Nov 10. doi: 10.3892/or.2020.7844.
    >> Share

    October 2020
  37. ZHANG H, Hu L, Cheng M, Wang Q, et al
    The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
    Oncol Rep. 2020 Oct 9. doi: 10.3892/or.2020.7798.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016